# BioRestorative Therapies Inc. (BRTX)

Source: https://www.quantisnow.com/company/BRTX
Generated: 2026-11-22T22:46:20.040Z

- Ticker: BRTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Managed Health Care
- SEC CIK: 0001505497
- Website: biorestorative.com

## About

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100 that has completed Phase 1 clinical trials is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate, which is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue (BAT). In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

## Latest BRTX news and filings

- 2026-11-12 21:56 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-leadership-update-financial-6788653)
- 2026-10-09 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-biorestorative-therapies-inc-6742863)
- 2026-10-06 12:49 UTC [Analyst Downgrade] [BioRestorative Therapies downgraded by Maxim Group](https://www.quantisnow.com/insight/biorestorative-therapies-downgraded-by-maxim-group-6738406)
- 2026-09-11 13:29 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-leadership-update-financial-6712644)
- 2026-09-10 20:30 UTC [SEC Form 8-K] [Amendment: BioRestorative Therapies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-biorestorative-therapies-inc-filed-sec-form-8-k-changes-in-6711823)
- 2026-09-02 21:29 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-material-modification-to-6703715)
- 2026-09-02 21:27 UTC [BioRestorative Therapies Announces Reverse Stock Split](https://www.quantisnow.com/insight/biorestorative-therapies-announces-reverse-stock-split-6703705)
- 2026-08-25 21:00 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-notice-of-delisting-6694545)
- 2026-08-14 20:25 UTC [SEC Form NT 10-Q filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-biorestorative-therapies-inc-6683158)
- 2026-08-14 20:15 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-other-events-financial-6683071)
- 2026-07-30 22:54 UTC [SEC Form 3] [SEC Form 3 filed by new insider Randhawa Esha](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-randhawa-esha-6656731)
- 2026-07-24 19:03 UTC [SEC Form 3] [SEC Form 3 filed by new insider Brown Steven Collier](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-brown-steven-collier-6648199)
- 2026-07-16 21:30 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-leadership-update-financial-6640194)
- 2026-06-25 12:15 UTC [BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform](https://www.quantisnow.com/insight/biorestorative-therapies-announces-completion-of-brtx-100-phase-2-manufacturing-highlighting-6615201)
- 2026-06-18 20:32 UTC [SEC Form 3] [SEC Form 3 filed by new insider Grasso Mika](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-grasso-mika-6609076)
- 2026-06-18 16:39 UTC [SEC Form 3] [SEC Form 3 filed by new insider Dhaliwal Jatinder](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-dhaliwal-jatinder-6608288)
- 2026-06-18 12:15 UTC [Leadership Update] [BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth](https://www.quantisnow.com/insight/biorestorative-therapies-strengthens-leadership-with-appointment-of-healthcare-executive-zachary-6607994)
- 2026-06-17 21:01 UTC [SEC Form 3] [SEC Form 3 filed by new insider Field Katharyn](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-field-katharyn-6607163)
- 2026-06-12 21:00 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-leadership-update-financial-6600955)
- 2026-06-12 20:56 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-entry-into-a-6600937)
- 2026-05-29 21:07 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-leadership-update-submission-6579845)
- 2026-05-27 11:45 UTC [Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)](https://www.quantisnow.com/insight/kaos-capital-announces-acquisition-of-49-stake-in-biorestorative-therapies-6573841)
- 2026-05-26 15:00 UTC [BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data](https://www.quantisnow.com/insight/biorestorative-completes-phase-2-dosing-of-brtx-100-advancing-lead-regenerative-6571698)
- 2026-05-14 20:31 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-biorestorative-therapies-inc-6554455)
- 2026-05-13 15:00 UTC [BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals](https://www.quantisnow.com/insight/biorestorative-therapies-presents-new-preclinical-data-at-isct-2026-highlighting-6550260)
- 2026-05-07 16:00 UTC [BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease](https://www.quantisnow.com/insight/biorestorative-therapies-reports-expanded-phase-2-blinded-dataset-for-brtx-100-6538226)
- 2026-05-01 20:17 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-leadership-update-6526982)
- 2026-04-30 20:10 UTC [SEC Form 424B3] [SEC Form 424B3 filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-biorestorative-therapies-inc-6524379)
- 2026-04-30 14:36 UTC [BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform](https://www.quantisnow.com/insight/biorestorative-therapies-to-present-new-data-at-isct-2026-highlighting-6523405)
- 2026-04-29 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-biorestorative-therapies-inc-6519750)
- 2026-04-27 20:05 UTC [SEC Form POS AM filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-biorestorative-therapies-inc-6516294)
- 2026-04-23 21:12 UTC [SEC Form 8-K] [BioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/biorestorative-therapies-inc-filed-sec-form-8-k-regulation-fd-disclosure-6513134)
- 2026-04-21 12:00 UTC [BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform](https://www.quantisnow.com/insight/biorestorative-therapies-announces-strategic-partnership-with-global-dermatology-leader-dr-6507688)
- 2026-04-20 21:30 UTC [SEC Form POS AM filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-biorestorative-therapies-inc-6507126)
- 2026-04-13 21:22 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-biorestorative-therapies-inc-6498238)
- 2026-04-07 12:15 UTC [BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform](https://www.quantisnow.com/insight/biorestorative-therapies-announces-strategic-collaboration-with-203-creates-to-build-6490443)
- 2026-04-03 18:46 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-biorestorative-therapies-inc-6487169)
- 2026-03-30 12:00 UTC [BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease](https://www.quantisnow.com/insight/biorestorative-therapies-reports-positive-phase-2-blinded-data-for-brtx-100-6475880)
- 2026-03-26 20:20 UTC [SEC Form 10-K] [SEC Form 10-K filed by BioRestorative Therapies Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-biorestorative-therapies-inc-6471308)
- 2026-03-19 12:00 UTC [BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease](https://www.quantisnow.com/insight/biorestorative-therapies-to-present-positive-phase-2-blinded-data-for-6460685)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BRTX
- Earnings history: https://www.quantisnow.com/earnings/BRTX
- Dividend history: https://www.quantisnow.com/dividends/BRTX
- Insider transactions: https://www.quantisnow.com/insiders/BRTX
- Options chain: https://www.quantisnow.com/options/BRTX
- SEC 8-K filings only: https://www.quantisnow.com/company/BRTX/8-k
- RSS and alerts for BRTX: https://www.quantisnow.com/docs/rss-feeds.md
